올리고뉴클레오타이드 합성 시장 분석 및 예측(-2035년) : 유형, 제품 유형, 서비스, 기술, 용도, 형태, 최종 사용자, 공정, 기능, 단계

Oligonucleotide Synthesis Market is anticipated to expand from $6.2 billion in 2024 to $15.4 billion by 2034, growing at a CAGR of approximately 10.2%. The Oligonucleotide Synthesis Market encompasses the production of short DNA or RNA molecules, pivotal in genetic research, diagnostics, and therapeutics. This market is driven by advancements in synthetic biology, personalized medicine, and increased demand for nucleic acid-based therapies. Key focuses include innovation in synthesis techniques, scalability, and cost-effectiveness to meet the rising need for high-quality oligonucleotides in research and clinical applications.

The Oligonucleotide Synthesis Market is experiencing robust growth, propelled by the increasing application of oligonucleotides in research and therapeutics. Among the segments, the synthesized oligonucleotides segment is the top performer, driven by its critical role in diagnostics and therapeutic applications. Custom oligonucleotides, tailored for specific research needs, are witnessing substantial demand, reflecting their significance in personalized medicine. The consumables sub-segment, encompassing reagents and enzymes, is the second-highest performer, essential for efficient synthesis processes. The services segment, including contract manufacturing and sequencing services, is also gaining traction due to the outsourcing trend among biotech firms. Automated synthesizers are becoming indispensable, offering precision and scalability, thus enhancing market dynamics. Furthermore, the growing focus on RNA-based therapeutics and the development of novel synthesis technologies are key drivers, presenting lucrative opportunities for market participants. Investments in R&D and strategic collaborations are expected to further propel market expansion and innovation.

The Oligonucleotide Synthesis Market is experiencing dynamic shifts in market share, driven by competitive pricing strategies and the introduction of innovative products. Companies are leveraging cutting-edge technologies to enhance product offerings, thereby attracting a diverse clientele across various sectors. The market is witnessing a surge in demand for custom oligonucleotides, which is further fueling competition among key players. This competitive environment is fostering strategic alliances and collaborations, enabling firms to expand their product portfolios and enhance their market presence. In terms of competition benchmarking, major players are continually assessing their market positions to optimize their strategic initiatives. Regulatory influences play a pivotal role, with stringent guidelines impacting product development and market entry. The market landscape is shaped by rigorous compliance standards, particularly in regions like North America and Europe, where regulatory frameworks are more stringent. Companies are investing in research and development to navigate these regulatory challenges, ensuring product efficacy and safety. This strategic focus is essential for sustaining growth in a highly competitive environment.

Geographical Overview:

The Oligonucleotide Synthesis Market is witnessing remarkable growth across various regions, each characterized by unique dynamics. North America leads, driven by substantial investments in biotechnology and pharmaceutical research. The presence of major biotech firms and research institutions further accelerates market expansion. Europe follows closely, with a strong emphasis on innovative healthcare solutions and government support for biotechnology. The region's robust regulatory framework enhances market stability and growth prospects. In Asia Pacific, rapid advancements in genomics and personalized medicine are propelling market growth. Countries like China and India are emerging as key players, fueled by increasing investments in research and development. Latin America and the Middle East & Africa present burgeoning opportunities. Latin America is experiencing a surge in biotech startups and collaborations, while the Middle East & Africa are investing in healthcare infrastructure to support oligonucleotide synthesis. These regions are recognizing the potential of oligonucleotide technologies in advancing medical research and therapeutic applications.

The global oligonucleotide synthesis market is navigating complex challenges shaped by tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea, key players in biotechnology, are adapting to trade tensions by enhancing domestic capabilities and forging strategic alliances. China is intensifying its focus on self-reliance in oligonucleotide production, driven by export limitations and geopolitical pressures. Taiwan continues to be a pivotal supplier, yet remains vulnerable to regional conflicts. The parent market is experiencing robust growth, propelled by advancements in personalized medicine and genetic research. By 2035, the market is anticipated to evolve through strategic diversification and technological innovation. Middle East conflicts contribute to supply chain disruptions and volatile energy prices, indirectly influencing production costs and market stability.

Key Trends and Drivers:

The oligonucleotide synthesis market is experiencing robust growth, driven by advancements in personalized medicine and biotechnology. Key trends include the increasing demand for custom oligonucleotides, which are essential in applications such as diagnostics, therapeutics, and research. The rise of gene editing technologies, particularly CRISPR, is significantly boosting the market as researchers and companies seek precise and efficient synthesis techniques. Moreover, the expansion of synthetic biology is fueling the need for high-quality oligonucleotides. This trend is supported by the growing investments in genomics and proteomics research. The healthcare industry's shift towards precision medicine is another crucial driver, as it relies heavily on oligonucleotide-based therapies. Additionally, the increasing prevalence of genetic disorders and infectious diseases is propelling the demand for innovative oligonucleotide solutions. Opportunities abound in emerging markets where healthcare infrastructure is evolving, and the adoption of advanced biotechnologies is accelerating. Companies that provide cost-effective and scalable synthesis solutions stand to gain a competitive edge. Furthermore, the integration of automation and artificial intelligence in synthesis processes is poised to enhance efficiency and reduce costs, offering further growth potential in this dynamic market.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by Form
• 2.7 Key Market Highlights by End User
• 2.8 Key Market Highlights by Process
• 2.9 Key Market Highlights by Functionality
• 2.10 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Custom Oligonucleotides
  • 4.1.2 Pre-designed Oligonucleotides
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Synthesized Oligonucleotides
  • 4.2.2 Reagents
  • 4.2.3 Equipment
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Custom Synthesis
  • 4.3.2 Oligo Purification
  • 4.3.3 Oligo Modification
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Solid-phase Synthesis
  • 4.4.2 Solution-phase Synthesis
  • 4.4.3 Enzymatic Synthesis
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Research
  • 4.5.2 Therapeutics
  • 4.5.3 Diagnostics
  • 4.5.4 Gene Synthesis
• 4.6 Market Size & Forecast by Form (2020-2035)
  • 4.6.1 Liquid
  • 4.6.2 Lyophilized
• 4.7 Market Size & Forecast by End User (2020-2035)
  • 4.7.1 Academic Research Institutes
  • 4.7.2 Pharmaceutical Companies
  • 4.7.3 Biotechnology Companies
  • 4.7.4 Diagnostic Laboratories
• 4.8 Market Size & Forecast by Process (2020-2035)
  • 4.8.1 DNA Synthesis
  • 4.8.2 RNA Synthesis
• 4.9 Market Size & Forecast by Functionality (2020-2035)
  • 4.9.1 Antisense Oligonucleotides
  • 4.9.2 siRNA
  • 4.9.3 miRNA
• 4.10 Market Size & Forecast by Stage (2020-2035)
  • 4.10.1 Preclinical
  • 4.10.2 Clinical
  • 4.10.3 Commercial

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 Form
    • 5.2.1.7 End User
    • 5.2.1.8 Process
    • 5.2.1.9 Functionality
    • 5.2.1.10 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 Form
    • 5.2.2.7 End User
    • 5.2.2.8 Process
    • 5.2.2.9 Functionality
    • 5.2.2.10 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 Form
    • 5.2.3.7 End User
    • 5.2.3.8 Process
    • 5.2.3.9 Functionality
    • 5.2.3.10 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 Form
    • 5.3.1.7 End User
    • 5.3.1.8 Process
    • 5.3.1.9 Functionality
    • 5.3.1.10 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 Form
    • 5.3.2.7 End User
    • 5.3.2.8 Process
    • 5.3.2.9 Functionality
    • 5.3.2.10 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 Form
    • 5.3.3.7 End User
    • 5.3.3.8 Process
    • 5.3.3.9 Functionality
    • 5.3.3.10 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 Form
    • 5.4.1.7 End User
    • 5.4.1.8 Process
    • 5.4.1.9 Functionality
    • 5.4.1.10 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 Form
    • 5.4.2.7 End User
    • 5.4.2.8 Process
    • 5.4.2.9 Functionality
    • 5.4.2.10 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 Form
    • 5.4.3.7 End User
    • 5.4.3.8 Process
    • 5.4.3.9 Functionality
    • 5.4.3.10 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 Form
    • 5.4.4.7 End User
    • 5.4.4.8 Process
    • 5.4.4.9 Functionality
    • 5.4.4.10 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 Form
    • 5.4.5.7 End User
    • 5.4.5.8 Process
    • 5.4.5.9 Functionality
    • 5.4.5.10 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 Form
    • 5.4.6.7 End User
    • 5.4.6.8 Process
    • 5.4.6.9 Functionality
    • 5.4.6.10 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 Form
    • 5.4.7.7 End User
    • 5.4.7.8 Process
    • 5.4.7.9 Functionality
    • 5.4.7.10 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 Form
    • 5.5.1.7 End User
    • 5.5.1.8 Process
    • 5.5.1.9 Functionality
    • 5.5.1.10 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 Form
    • 5.5.2.7 End User
    • 5.5.2.8 Process
    • 5.5.2.9 Functionality
    • 5.5.2.10 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 Form
    • 5.5.3.7 End User
    • 5.5.3.8 Process
    • 5.5.3.9 Functionality
    • 5.5.3.10 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 Form
    • 5.5.4.7 End User
    • 5.5.4.8 Process
    • 5.5.4.9 Functionality
    • 5.5.4.10 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 Form
    • 5.5.5.7 End User
    • 5.5.5.8 Process
    • 5.5.5.9 Functionality
    • 5.5.5.10 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 Form
    • 5.5.6.7 End User
    • 5.5.6.8 Process
    • 5.5.6.9 Functionality
    • 5.5.6.10 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 Form
    • 5.6.1.7 End User
    • 5.6.1.8 Process
    • 5.6.1.9 Functionality
    • 5.6.1.10 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 Form
    • 5.6.2.7 End User
    • 5.6.2.8 Process
    • 5.6.2.9 Functionality
    • 5.6.2.10 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 Form
    • 5.6.3.7 End User
    • 5.6.3.8 Process
    • 5.6.3.9 Functionality
    • 5.6.3.10 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 Form
    • 5.6.4.7 End User
    • 5.6.4.8 Process
    • 5.6.4.9 Functionality
    • 5.6.4.10 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 Form
    • 5.6.5.7 End User
    • 5.6.5.8 Process
    • 5.6.5.9 Functionality
    • 5.6.5.10 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Integrated DNA Technologies
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Eurofins Genomics
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 LGC Biosearch Technologies
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Gen Script Biotech
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Twist Bioscience
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Bio- Synthesis
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Sigma- Aldrich
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Biomers
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 ATDBio
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Tri Link Bio Technologies
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Gene Link
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Bioneer
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 LGC Axolabs
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Alnylam Pharmaceuticals
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Chem Genes
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Glen Research
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Kaneka Eurogentec
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Nitto Denko Avecia
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Synbio Technologies
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Base Pair Biotechnologies
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us